The histopathology characterizing Alzheimer's disease (AD) involves deposition of amyloid protein (Abeta) in brain parenchyma and cerebral vessel walls, and intraneuronal neurofibrillary tangles. Some hereditary forms of the disease involve peculiar Abeta deposition. In a rare familial disorder, hereditary cerebral hemorrhage with amyloidosis, Dutch type (HCHWA-D), Abeta is deposited predominantly in the brain vasculature, causing strokes and early death. Abeta is an aberrant degradation product of an amyloid precursor protein (APP). To date, mutations in the APP gene have been found only in HCHWA-D and in a few families with familial AD (FAD) of early age of onset. The mutations segregate with the disease, indicating a possible role in amyloidogenesis. HCHWA-D and FAD are good models to examine the common features of diseases involving Abeta deposition as well as the causes of the clinicopathological differences between AD, FAD and HCHWA-D. We propose: 1) to screen for mutations in the APP gene in families with early-onset FAD and study the effect of specific mutations on the rate and site of amyloid deposition; 2) to develop an animal model by constructing transgenic mice, in order to test whether mutations in the APP gene cause accelerated Abeta deposition in specific sites of the brain. This model enables analysis of the pathological effect of amyloid deposition, and testing therapeutic approaches.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Unknown (R35)
Project #
5R35AG010953-05
Application #
5204869
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1996
Total Cost
Indirect Cost
Vidal, R; Revesz, T; Rostagno, A et al. (2000) A decamer duplication in the 3' region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc Natl Acad Sci U S A 97:4920-5
Mead, S; James-Galton, M; Revesz, T et al. (2000) Familial British dementia with amyloid angiopathy: early clinical, neuropsychological and imaging findings. Brain 123 ( Pt 5):975-91
Baumann, M H; Kallijarvi, J; Lankinen, H et al. (2000) Apolipoprotein E includes a binding site which is recognized by several amyloidogenic polypeptides. Biochem J 349:77-84
Rostagno, A; Vidal, R; Kaplan, B et al. (1999) pH-dependent fibrillogenesis of a VkappaIII Bence Jones protein. Br J Haematol 107:835-43
Poduslo, J F; Curran, G L; Kumar, A et al. (1999) Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma. J Neurobiol 39:371-82
Koudinov, A R; Berezov, T T; Koudinova, N V (1998) Alzheimer's amyloid beta and lipid metabolism: a missing link? FASEB J 12:1097-9
Crawford, F; Soto, C; Suo, Z et al. (1998) Alzheimer's beta-amyloid vasoactivity: identification of a novel beta-amyloid conformational intermediate. FEBS Lett 436:445-8
Wisniewski, T; Dowjat, W K; Buxbaum, J D et al. (1998) A novel Polish presenilin-1 mutation (P117L) is associated with familial Alzheimer's disease and leads to death as early as the age of 28 years. Neuroreport 9:217-21
Soto, C; Sigurdsson, E M; Morelli, L et al. (1998) Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 4:822-6
Permanne, B; Perez, C; Soto, C et al. (1997) Detection of apolipoprotein E/dimeric soluble amyloid beta complexes in Alzheimer's disease brain supernatants. Biochem Biophys Res Commun 240:715-20

Showing the most recent 10 out of 50 publications